Flow Medical closes $6 million round for HELYX-PE system

By Olivia Hart

Flow Medical said it closed a $6 million financing round to advance HELYX-PE, an investigational catheter system for treating pulmonary embolism. The company did not name the strategic medical device investors or disclose the round’s valuation or whether the capital came through equity or debt. That leaves the financial shape and commercial backing of the deal less clear than the headline figure.

What does the $6 million financing fund?

Flow Medical, a medical technology company spun out of the University of Chicago, said proceeds will support first-in-human clinical evaluation of its HELYX-PE System. The money will also fund continued product development and manufacturing, plus preparations for a U.S. pivotal study intended to support a future submission to the FDA.

Flow Medical said the financing builds on extensive preclinical development and testing as the company prepares to transition into clinical evaluation. Proceeds will also support the manufacturing, quality, and regulatory work needed to advance HELYX-PE through its next stages.

The plan spans early human testing through pivotal-study preparation, but the announcement supplies no trial enrollment, endpoint, timetable, or budget beyond $6 million. Investors are backing a development program, not evidence of safety, efficacy, or approval.

The round funds the next development phase, while leaving clinical and regulatory execution unresolved.

How is HELYX-PE designed to address pulmonary embolism?

Flow Medical describes pulmonary embolism as a potentially life-threatening condition caused by blood clots that obstruct blood flow to the lungs. The company said catheter-based therapies have expanded treatment options, but opportunities remain to improve thrombolytic-drug delivery and physicians’ assessment of patient response during treatment.

The HELYX-PE System is an investigational 9 French catheter-directed thrombolysis platform. It combines an expandable infusion scaffold, integrated angiography, and continuous pulmonary artery pressure monitoring.

Flow Medical says the design aims to improve drug distribution, streamline procedures, and give physicians real-time information for treatment decisions. Those are design objectives rather than demonstrated clinical gains; the announcement offers no comparative outcomes for existing catheter approaches.

The platform bundles delivery and monitoring functions, but its value still depends on human testing.

Who built the system, and what do they claim?

Interventional physicians and Flow Medical co-founders Osman Ahmed, M.D., and Jonathan Paul, M.D., designed the system. Paul said the team sought to translate clinical experience into a new treatment approach.

“We believe there’s a tremendous opportunity to improve how pulmonary embolism is treated,” says Jennifer Fried, CEO and co-founder of Flow Medical. “Our goal is to give physicians better tools and better information to deliver safer, more efficient, and more personalized care.”

Her statement defines a clinical ambition, not a result. Flow Medical provided no patient data, benchmark, or comparison showing that HELYX-PE delivers safer, more efficient, or more personalized care than current treatment.

Jonathan Paul, M.D., is an Associate Professor of Medicine and Director of the Pulmonary Embolism Response Team (PERT) at UChicago Medicine. The PERT Consortium recognizes UChicago Medicine’s Heart and Vascular Center as a Comprehensive Center of Excellence for pulmonary embolism care.

Flow Medical said the multidisciplinary PERT program evaluates approximately 500 patients annually. The company linked that volume to firsthand insight into treatment challenges and opportunities for improvement.

“Having spent years caring for patients with pulmonary embolism, we’ve seen firsthand where existing treatments fall short and how much opportunity there is to improve care,” says Dr. Paul. His comments connect those treatment gaps to Flow Medical’s decision to build a new device.

Dr. Paul also said: “It’s incredibly exciting to be approaching the opportunity to evaluate this technology in our first patients. Translating what we’ve learned in clinical practice into a new approach to treatment is exactly why we started Flow.” Flow Medical will test that approach in first-in-human clinical evaluation.

The founders bring relevant experience, but only controlled human testing can establish the system’s clinical value.

What must happen before an FDA submission?

Flow Medical said the proceeds will support first-in-human evaluation and preparations for a U.S. pivotal study intended to support a future FDA submission. The announcement did not identify patients, trial sites, study size, primary endpoints, completion dates, or required regulatory interactions.

The financing also leaves commercial questions open: investor identities, deal terms, manufacturing scale, and any additional capital required before commercialization. None can be answered from the announcement.

At this stage, HELYX-PE remains investigational. No human safety or efficacy findings, regulatory clearance, or commercial performance appear in Flow Medical’s disclosure.

Flow Medical’s next test is whether HELYX-PE can turn its monitoring and delivery design into safer, more efficient, and more personalized care in human patients. The $6 million funds that test, not a proven outcome.